Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:CHRO

Chromocell Therapeutics (CHRO) Stock Price, News & Analysis

Chromocell Therapeutics logo

About Chromocell Therapeutics Stock (NYSE:CHRO)

Advanced Chart

Key Stats

Today's Range
$1.23
$1.48
50-Day Range
$1.34
$13.50
52-Week Range
$4.50
$38.00
Volume
194,032 shs
Average Volume
47,337 shs
Market Capitalization
$8.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CHRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHRO Stock News Headlines

Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Ligand subsidiaries, Chromocell Therapeutics to merge
Chromocell Therapeutics Corp (CHRO)
Channel Therapeutics Corporation (CHRO)
See More Headlines

CHRO Stock Analysis - Frequently Asked Questions

Chromocell Therapeutics's stock reverse split on Wednesday, July 2nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Chromocell Therapeutics (CHRO) raised $7 million in an initial public offering (IPO) on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share.

Company Calendar

Today
9/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CHRO
Previous Symbol
NYSE:CHRO
CIK
1919246
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.38 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-453.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.60
Quick Ratio
0.60

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.65) per share
Price / Book
-0.81

Miscellaneous

Outstanding Shares
6,485,000
Free Float
5,039,000
Market Cap
$8.69 million
Optionable
N/A
Beta
3.63

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:CHRO) was last updated on 9/7/2025 by MarketBeat.com Staff
From Our Partners